PHAT
Phathom Pharmaceuticals, Inc.
$7.40
+0.40
(+5.71%)
Mkt Cap
603.52M
Volume
1,721,068
52W Range
6.52-18.31
Sector
Healthcare
Beta
0.50
EPS (TTM)
-1.28 USD
P/E Ratio
-5.48
Revenue (TTM)
239.66M USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 175.11M | 55.25M | 682,000 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (221.25M) | (334.33M) | (201.59M) | (197.72M) | (143.88M) | (129.07M) | (209.74M) | (1.29M) |
| EPS | -3.03 | -5.29 | -3.93 | -5.70 | -4.00 | -4.01 | -8.48 | -0.15 |
| Free Cash Flow | (166.78M) | (266.90M) | (139.21M) | (147.57M) | (148.78M) | (70.73M) | (61.76M) | (1.02M) |
| FCF / Share | -2.29 | -4.22 | -2.71 | -3.77 | -4.02 | -2.13 | -2.50 | -0.12 |
| Operating CF | (166.78M) | (266.77M) | (137.58M) | (146.53M) | (148.46M) | (69.69M) | (36.51M) | (1.02M) |
| Total Assets | 259.15M | 378.32M | 413.84M | 164.81M | 189.43M | 295.11M | 257.18M | 902,000 |
| Total Debt | 211.80M | 201.91M | 139.03M | 97.07M | 91.34M | 49.02M | 23.57M | 1.95M |
| Cash & Equiv | 129.97M | 297.26M | 381.39M | 155.38M | 183.26M | 287.50M | 243.76M | 879,000 |
| Book Value | (438.17M) | (253.58M) | (72.76M) | (74.81M) | 72.16M | 194.27M | 227.96M | (1.29M) |
| Return on Equity | N/A | N/A | N/A | N/A | -1.99 | -0.66 | -0.92 | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 74.27M | 58.30M | 57.58M | 49.50M | 39.50M | 28.52M | 29.66M | 16.35M | 7.32M | 1.91M | 682,000 | 0 |
| Net Income | (17.58M) | (30.37M) | (21.15M) | (29.97M) | (75.81M) | (94.32M) | (74.45M) | (85.58M) | (91.45M) | (82.85M) | (79.57M) | (43.24M) |
| EPS | -0.21 | -0.37 | -0.29 | -0.41 | -1.05 | -1.31 | -1.05 | -1.32 | -1.56 | -1.42 | -1.39 | -0.76 |
| Free Cash Flow | (1.97M) | (15.71M) | (4.89M) | (14.14M) | (62.73M) | (84.95M) | (63.46M) | (63.49M) | (70.77M) | (69.06M) | (44.27M) | (32.85M) |
| FCF / Share | -0.02 | -0.19 | -0.07 | -0.19 | -0.87 | -1.18 | -0.89 | -0.98 | -1.21 | -1.18 | -0.77 | -0.58 |
| Operating CF | (1.93M) | (15.65M) | (5.00M) | (14.12M) | (62.73M) | (84.93M) | (63.46M) | (63.57M) | (70.72M) | (69.02M) | (43.80M) | (31.91M) |
| Total Assets | 327.07M | 305.12M | 259.15M | 240.29M | 250.22M | 294.21M | 378.32M | 387.04M | 319.38M | 356.50M | 413.84M | 236.99M |
| Total Debt | 167.11M | 166.30M | 211.80M | 209.81M | 205.97M | 203.56M | 201.91M | 176.41M | 175.28M | 150.04M | 139.03M | 100.61M |
| Cash & Equiv | 182.48M | 180.90M | 129.97M | 135.16M | 149.57M | 212.31M | 297.26M | 334.68M | 276.24M | 322.23M | 381.39M | 213.68M |
| Book Value | (344.27M) | (336.95M) | (438.17M) | (422.53M) | (405.83M) | (338.38M) | (253.58M) | (187.11M) | (233.83M) | (148.50M) | (72.76M) | (17.77M) |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
PHAT News
Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
Phathom Pharmaceuticals (NASDAQ:PHAT) Reaches New 12-Month Low – Time to Sell?
PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law
PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Phathom Pharmaceuticals, Inc. (PHAT)
PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)
PHAT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Phathom Pharmaceuticals
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call Transcript